Regulatory or Investigational Status
Retatrutide remains investigational. FDA states that it is not a component of an approved drug and has not been established as safe and effective for any condition. Catalog inclusion does not change that status. [4]
Mechanisms or Pathways Under Investigation
The research combines incretin pathways involved in glucose and appetite regulation with glucagon-receptor signaling. The contribution of each pathway to overall clinical effects is a mechanistic question; receptor activity alone does not establish a treatment benefit. [1][2]
Major Research Context
The 2023 obesity trial enrolled adults with obesity or overweight and a related condition, without diabetes. A separate trial studied adults with type 2 diabetes. An exploratory substudy assessed liver fat. The phase 3 TRIUMPH program extends investigation to obesity and related conditions. These are different populations and endpoints. [1][2][3][7]
Published Research Highlights
Human phase 2 · Obesity
At 48 weeks, the largest mean weight reduction among the studied groups was 24.2%. Gastrointestinal adverse events and increases in heart rate were reported. The result is a trial average, not a guarantee. [1]
Human phase 2 · Type 2 diabetes
Rosenstock and colleagues assessed glycated hemoglobin and body-weight changes against placebo and an active comparator. Results supported further investigation. [2]
Exploratory liver-fat research
A phase 2a analysis examined liver-fat changes using imaging. Such findings do not by themselves establish long-term liver or cardiovascular outcomes. [3]
Sponsor-reported phase 3 updates · Separate evidence category
Lilly’s May 2026 TRIUMPH-1 release reported up to 28.3% mean weight reduction at 80 weeks under its efficacy estimand. Its December 2025 TRIUMPH-4 release reported up to 28.7% at 68 weeks. These citations are company announcements, not peer-reviewed publications; their analysis populations and assumptions matter. The sponsor also announced TRIUMPH-2 and TRIUMPH-3 topline results in July 2026. [5][6][7]
Evidence Level and Research Limitations
Dose groups, selected participants and limited follow-up constrain interpretation. Sponsor announcements are identified separately and are not presented as independently peer-reviewed findings. Results from clinical-trial material cannot be transferred to catalog vials. [1][2][3][4]
Selected Scientific References
- Jastreboff et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. NEJM, 2023. ↗Human phase 2 trial
- Rosenstock et al. Retatrutide in people with type 2 diabetes. The Lancet, 2023. ↗Human phase 2 trial
- Sanyal et al. Retatrutide for metabolic dysfunction-associated steatotic liver disease. Nature Medicine, 2024. ↗Human exploratory phase 2a analysis
- FDA. Current information on unapproved GLP-1 drugs, including retatrutide. ↗Official regulatory material
- Eli Lilly. TRIUMPH-1 topline announcement, 21 May 2026. ↗Sponsor news release · Not a peer-reviewed publication
- Eli Lilly. TRIUMPH-4 topline announcement, 11 December 2025. ↗Sponsor news release · Not a peer-reviewed publication
- Eli Lilly. Retatrutide development overview, updated July 2026. ↗Sponsor development information
Educational and Research Disclaimer
This page is for educational and scientific-reference purposes. It does not provide medical advice, diagnosis, treatment recommendations, dosing guidance or instructions for human use. References concern the specific materials and conditions studied; they are not evidence that an AUVYRON product has been evaluated in those studies. Product presentations are catalog identifiers, not use instructions.
FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.